Project RD.06.SPR.202685 – A study to assess the efficacy and safety of nemolizumab (CD14152) insubjects with prurigo…

Basic data

Acronym:
RD.06.SPR.202685
Title:
A study to assess the efficacy and safety of nemolizumab (CD14152) insubjects with prurigo nodularis (PN)
Duration:
04/05/2020 to 30/09/2022
Abstract / short description:
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the
Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis
Keywords:
Prurigo nodularis

Involved staff

Managers

Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine

Contact persons

Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Department of Dermatology
Hospitals and clinical institutes
Faculty of Medicine

Funders

La Tour-de-Peilz, Switzerland
Help

will be deleted permanently. This cannot be undone.